This 1967 Mayo Clinic retrospective series characterizes 600 pathologically confirmed osteosarcomas treated between 1909 and 1964. It asks who gets this tumor, where it occurs, and what fraction of patients survive — all before the advent of chemotherapy. It is the definitive natural-history description of osteosarcoma in the surgical-only era.
The number every oncology trainee must own: 20.3% five-year survival with surgery alone. When Rosen and colleagues introduced neoadjuvant multi-agent chemotherapy in the 1970s and survival climbed toward 60–70%, that improvement was only legible because Dahlin's series had precisely characterized the surgical baseline.
When you evaluate an osteosarcoma, location shapes prognosis more than grade or subtype. Distal extremity tumors (below elbow or knee) carry a 35.5% five-year survival vs. 9.4% for axial and girdle tumors — a difference that is statistically significant and reflects surgical accessibility, not tumor biology.
Two special populations carry distinctly worse prognosis and are high-yield for boards: Post-irradiation osteosarcoma. 0% survival beyond three years (0/16 patients). Paget's-associated osteosarcoma. Only 3/20 long-term survivors, typically presenting in patients over 60.
This paper also provides early justification for pulmonary metastasectomy: 2 of 6 patients with resected solitary pulmonary metastases became long-term survivors. A signal that prefigured modern aggressive metastasis management.
This 1967 Mayo Clinic retrospective series characterizes 600 pathologically confirmed osteosarcomas treated between 1909 and 1964. It asks who gets this tumor, where it occurs, and what fraction of patients survive — all before the advent of chemotherapy. It is the definitive natural-history description of osteosarcoma in the surgical-only era.
The number every oncology trainee must own: 20.3% five-year survival with surgery alone. When Rosen and colleagues introduced neoadjuvant multi-agent chemotherapy in the 1970s and survival climbed toward 60–70%, that improvement was only legible because Dahlin's series had precisely characterized the surgical baseline.
When you evaluate an osteosarcoma, location shapes prognosis more than grade or subtype. Distal extremity tumors (below elbow or knee) carry a 35.5% five-year survival vs. 9.4% for axial and girdle tumors — a difference that is statistically significant and reflects surgical accessibility, not tumor biology.
Two special populations carry distinctly worse prognosis and are high-yield for boards: Post-irradiation osteosarcoma. 0% survival beyond three years (0/16 patients). Paget's-associated osteosarcoma. Only 3/20 long-term survivors, typically presenting in patients over 60.
This paper also provides early justification for pulmonary metastasectomy: 2 of 6 patients with resected solitary pulmonary metastases became long-term survivors. A signal that prefigured modern aggressive metastasis management.